Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Pereira, Elena ^a   Camacho Vanegas, Olga ^a   Anand, Sanya ^a   Sebra, Robert ^a   Camacho, Sandra Catalina ^a   Garnar Wortzel, Leopold ^a   Nair, Navya ^a   Moshier, Erin ^a   Wooten, Melissa ^a   Uzilov, Andrew ^a   Chen, Rong ^a   Prasad Hayes, Monica ^a   Zakashansky, Konstantin ^a   Beddoe, Ann Marie ^a   Schadt, Eric ^a   Dottino, Peter ^a   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CIRCULATING TUMOR DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN TISSUE; MIDDLE AGED; OVERALL SURVIVAL; PERITONEUM CANCER; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; BLOOD; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; EXOME; GENETICS; GENITAL NEOPLASMS, FEMALE; MORTALITY; MUTATION; OVARIAN NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CA-125 ANTIGEN; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; EXOME; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 84956949472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145754     Document Type: Article

References (20)

1. American Cancer Society. Cancer Facts & Figs 2015 [Internet]. Atlanta: American Cancer Society; 2015. Available: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed 1 September 2015.
2. Buys SS. Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun. 8;305(22):2295. doi: 10. 1001/jama.2011.766 PMID: 21642681
3. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000 May; 82(9):1535-8. PMID: 10789720
4. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003 Oct; 91(1):46-50. PMID: 14529661
5. Testa AC, Di Legge A, Virgilio B, Bonatti M, Manfredi R, Mirk P, et al. Which imaging technique should we use in the follow up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol. 2014 Jul; 28(5):769-91. doi: 10.1016/j.bpobgyn. 2014.04.008 PMID: 24861246
6. Chang H-W, Lee SM, Goodman SN, Singer G, Cho SKR, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002 Nov. 20;94(22):1697-703. PMID: 12441325
7. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006 Sep; 1075:230-4. PMID: 17108216
8. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl J Med. 2013 Mar. 28;368(13):1199-209. doi: 10. 1056/NEJMoa1213261 PMID: 23484797
9. Freidin MB, Freydina DV, Leung M, Montero Fernandez A, Nicholson AG, Lim E. Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies. Clin Chem. 2015 Aug. 13.
10. Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015 Feb. 4.
11. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer. 2015 Jan 20;112(2):352-6. doi: 10. 1038/bjc.2014.609 PMID: 25490524
12. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug. 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021 PMID: 26311728
13. Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005 Sep; 193(3 Pt 1):662-7. PMID: 16150257
14. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb. 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094 PMID: 24553385
15. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012 May 30;4(136):136ra68. doi: 10.1126/scitranslmed.3003726 PMID: 22649089
16. Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia N Y N. 2014 Jan; 16(1):97-103.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer [Internet]. 2015. Available: http://www.nccn.org/professionals/physician-gls/pdf/ovarian. pdf. Accessed 1 September 2015.
18. Bast RC. CA 125 and the detection of recurrent ovarian cancer: A reasonably accurate biomarker for a difficult disease. Cancer. 2010 Apr. 7;116(12):2850-3. doi: 10.1002/cncr.25203 PMID: 20564390
19. McMeekin DS, Mannel RS, Di Saia PJ. CHAPTER 10: The Adnexal Mass. In: Clinical Gynecologic Oncology [Internet]. 8th ed. Elsevier; 2012. p. i. Available: http://linkinghub.elsevier.com/retrieve/pii/B9780323074193000242. Accessed 13 September 2015.
20. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006 Aug; 17(8):1234-8.